{
    "2021-06-01": [
        [
            {
                "time": "2021-05-31",
                "orginal_text": "A股融资融券日报：两融余额增加114.99亿元（5月31日）",
                "features": {
                    "keywords": [
                        "两融余额",
                        "增加"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物月报：“三胎”“七普”相继发布 医药空间广阔 继续把握赛道布局、大小兼备的思路",
                "features": {
                    "keywords": [
                        "三胎",
                        "七普",
                        "医药空间",
                        "赛道布局"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "八连阳！定增、回购、重组齐上阵，花样保壳迎转机",
                "features": {
                    "keywords": [
                        "八连阳",
                        "定增",
                        "回购",
                        "重组",
                        "保壳"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药(02196.HK)旗下用于治疗I型神经纤维瘤病新药获美FDA药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "新药",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "【行情】港股抗疫概念板块多数下行，康希诺生物跌超7%，歌礼制药跌近4%，复星医药跌超3%",
                "features": {
                    "keywords": [
                        "港股",
                        "抗疫概念",
                        "下行",
                        "康希诺生物",
                        "歌礼制药",
                        "复星医药"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药(02196.HK)作价人民币约5.53亿出售在建的台州浙东医院",
                "features": {
                    "keywords": [
                        "复星医药",
                        "出售",
                        "台州浙东医院"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药(02196.HK)拟斥资人民币250万参与设立合资公司",
                "features": {
                    "keywords": [
                        "复星医药",
                        "合资公司",
                        "投资"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}